The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the decade — and any financial miss, or negative data of any kind, will trigger outsized sell-offs.
This past week, for example, Amgen (AMGN) lost $12 billion in market value. Hims & Hers (HIMS) lost 10% in a single day in October when the FDA ended the shortage designation of Eli Lilly’s (LLY) drugs. (Its worst day on record was Nov. 14, down 24% after Amazon (AMZN) launched a direct prescription service modeled after the company.)
Last month was the most dramatic, when Lilly saw more than $127 billion in stock value wiped out at peak loss in a single day. The company missed analyst estimates on its diabetes and weight-loss drugs, Mounjaro and Zepbound. (Investors bought the Lilly dip and the loss was pared to $54 billion by market close).
The recovery in the stock came only after CEO David Ricks responded to an analyst question on an earnings call about the sales miss, saying that demand was up 25% quarter over quarter. The stock started to pick up right after that, according to Citi healthcare analyst Geoff Meacham.
How volatile is that? The move seen in Lilly’s stock is typically reserved for Magnificent Seven stocks. For example, the day after the election, Tesla’s (TSLA) market cap increased by $120 billion.
The day of Lilly’s loss, another company on its way into the GLP-1 space was grappling with what the sell-off could mean for its future.
Amgen CFO Peter Griffith told Yahoo Finance the company, whose GLP-1 candidate MariTide is still only in mid-stage clinical trials, was worried investors were going to change how they rewarded the company’s stock — from weighing overall performance to focusing on a single product.
“There’s no doubt that MariTide … will eclipse the rest of our news here in the near future,” Griffith said, unaware at the time he would face that exact fate two weeks later.
The company’s stock was hammered Nov. 12 after older MariTide data published by an analyst briefly appeared to highlight a problematic side effect, which was quickly waved off by other analysts and Amgen itself.
The potential for high returns has created an energy around the leading GLP-1 companies — and serves as a cautionary tale for those that will follow.
“There are more eyeballs on Novo and Lilly than any other stock in healthcare, by a mile. That alone is going to read more volatility,” said Mizuho’s healthcare sector expert Jared Holz.
Some investors are looking for consistently large returns quarter over quarter and only care about the GLP-1 drugs.
“No one even asks a question outside of obesity on the Lilly or Novo [earnings] conference calls. And they both have a bunch of other things going on,” Holz told Yahoo Finance.
Lilly is one of two market leaders in the space, along with Novo Nordisk (NVO), and could be the first $1 trillion healthcare company by market cap.
It’s why, despite having a diverse portfolio of products — including one of only two new Alzheimer’s drugs on the market — the weight-loss drug Zepbound and diabetes drug Mounjaro are weighing more heavily on the stock. And misses of those two products are triggering Wall Street action.
Goldman Sachs analyst Chris Shibutani believes that while Lilly may not ever reach $1 trillion, it has outperformed for two, and potentially three, years in a row despite the volatility.
“That’s also a pretty exclusive club, where a stock manages, for three years in a row, to outperform its peers,” Shibutani said.
Citi’s Meacham pointed out that some investors may only be holding Lilly and no other healthcare stocks. “The reason I think you saw such a huge move is that there are a lot of investors that … may only own one healthcare stock, and that’s Lilly,” Meacham said.
Goldman Sachs’ Shibutani similarly noted more general investors have a “FOMO” (fear of missing out) mindset impacting the stock.
He noted that there are two categories that have invoked that feeling for the past few years: artificial intelligence and obesity.
It’s “a bit of zeitgeist, sort of a cultural phenomenon,” Shibutani said.
Holz also noted that there could be more volatility ahead for GLP-1s.
“These things kind of tend to trade with a zero-sum game — rightly or wrongly,” he said.
Yahoo Finance editor Jared Blikre contributed to this report. Follow him @SPYJared.
Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee on most social media platforms @AnjKhem.
Read the latest financial and business news from Yahoo Finance
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
